A new publication involving insulin degludec was listed on August 7, 2026. The paper, titled "Insulin Efsitora Versus Degludec in Adults with Type 2 Diabetes Using Basal Insulin: QWINT-3 Japan Subgroup Analysis," appeared in the journal Diabetes Therapy: research, treatment and education of diabetes and related disorders.
The publication presents a subgroup analysis from the QWINT-3 study, focused on adults with type 2 diabetes who were already using basal insulin. It compares insulin efsitora with insulin degludec within a Japan-specific patient subgroup, according to the listing.
No additional details about study design, outcomes, or results were included in the event data provided. This brief reports only the existence and bibliographic details of the publication as indexed.
Readers interested in insulin degludec can consult the compound overview for further background and context.